TLR4-directed small molecules

Our lab is developing:

TLR4 agonists as novel vaccine adjuvants

 

WE ARE PARTNERS OF THE BACTIVAX PROJECT (EU FUNDED, ETN MARIE CURIE ACTION) FOR THE DEVELOPMENT OF NEW VACCINES DIRECTED AGAINST BACTERIA CAUSING PULMONARY INFECTIONS (RESISTANT BACTERIA SUCH AS MYCOBACTERIA, PSEUDOMONAS, TUBERCOLOSIS)

TLR4 antagonists as new drug leads for inflammatory syndromes and SARS.COV2- induced lethality

Read our recent paper on the use of TLR4 antagonist to reduce inflammatory bowel diseases

Read about the use of TLR4 blockers to reduce acute respiratory syndrome caused by Sars-Cov2